231 related articles for article (PubMed ID: 32690669)
1. In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases.
Clark PA; Sriramaneni RN; Jin WJ; Jagodinsky JC; Bates AM; Jaquish AA; Anderson BR; Le T; Lubin JA; Chakravarty I; Arthur IS; Heinze CM; Guy EI; Kler J; Klar KA; Carlson PM; Kim KM; Kuo JS; Morris ZS
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690669
[TBL] [Abstract][Full Text] [Related]
2. Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain.
Clark PA; Sriramaneni RN; Bates AM; Jin WJ; Jagodinsky JC; Hernandez R; Le T; Jeffery JJ; Marsh IR; Grudzinski JJ; Aluicio-Sarduy E; Barnhart TE; Anderson BR; Chakravarty I; Arthur IS; Kim K; Engle JW; Bednarz BP; Weichert JP; Morris ZS
Radiat Res; 2021 Jun; 195(6):522-540. PubMed ID: 33826741
[TBL] [Abstract][Full Text] [Related]
3.
Baniel CC; Heinze CM; Hoefges A; Sumiec EG; Hank JA; Carlson PM; Jin WJ; Patel RB; Sriramaneni RN; Gillies SD; Erbe AK; Schwarz CN; Pieper AA; Rakhmilevich AL; Sondel PM; Morris ZS
Front Immunol; 2020; 11():1610. PubMed ID: 32849544
[TBL] [Abstract][Full Text] [Related]
4. Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination.
Carlson PM; Patel RB; Birstler J; Rodriquez M; Sun C; Erbe AK; Bates AM; Marsh I; Grudzinski J; Hernandez R; Pieper AA; Feils AS; Rakhmilevich AL; Weichert JP; Bednarz BP; Sondel PM; Morris ZS
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639155
[TBL] [Abstract][Full Text] [Related]
5. Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization.
Jagodinsky JC; Bates AM; Clark PA; Sriramaneni RN; Havighurst TC; Chakravarty I; Nystuen EJ; Kim K; Sondel PM; Jin WJ; Morris ZS
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192087
[TBL] [Abstract][Full Text] [Related]
6. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
[TBL] [Abstract][Full Text] [Related]
7. Short-course neoadjuvant in situ vaccination for murine melanoma.
Aiken TJ; Komjathy D; Rodriguez M; Stuckwisch A; Feils A; Subbotin V; Birstler J; Gillies SD; Rakhmilevich AL; Erbe AK; Sondel PM
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039460
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8
Taggart D; Andreou T; Scott KJ; Williams J; Rippaus N; Brownlie RJ; Ilett EJ; Salmond RJ; Melcher A; Lorger M
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1540-E1549. PubMed ID: 29386395
[TBL] [Abstract][Full Text] [Related]
9. Depth of tumor implantation affects response to in situ vaccination in a syngeneic murine melanoma model.
Carlson PM; Mohan M; Rodriguez M; Subbotin V; Sun CX; Patel RB; Birstler J; Hank JA; Rakhmilevich AL; Morris ZS; Erbe AK; Sondel PM
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858849
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Specific Inhibition of
Morris ZS; Guy EI; Werner LR; Carlson PM; Heinze CM; Kler JS; Busche SM; Jaquish AA; Sriramaneni RN; Carmichael LL; Loibner H; Gillies SD; Korman AJ; Erbe AK; Hank JA; Rakhmilevich AL; Harari PM; Sondel PM
Cancer Immunol Res; 2018 Jul; 6(7):825-834. PubMed ID: 29748391
[No Abstract] [Full Text] [Related]
11. Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models.
Phadke MS; Li J; Chen Z; Rodriguez PC; Mandula JK; Karapetyan L; Forsyth PA; Chen YA; Smalley KSM
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056899
[TBL] [Abstract][Full Text] [Related]
12. Boiling histotripsy and in-situ CD40 stimulation improve the checkpoint blockade therapy of poorly immunogenic tumors.
Singh MP; Sethuraman SN; Miller C; Malayer J; Ranjan A
Theranostics; 2021; 11(2):540-554. PubMed ID: 33391491
[No Abstract] [Full Text] [Related]
13. In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade.
Mao C; Beiss V; Ho GW; Fields J; Steinmetz NF; Fiering S
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460333
[TBL] [Abstract][Full Text] [Related]
14. Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition.
Voeller J; Erbe AK; Slowinski J; Rasmussen K; Carlson PM; Hoefges A; VandenHeuvel S; Stuckwisch A; Wang X; Gillies SD; Patel RB; Farrel A; Rokita JL; Maris J; Hank JA; Morris ZS; Rakhmilevich AL; Sondel PM
J Immunother Cancer; 2019 Dec; 7(1):344. PubMed ID: 31810498
[TBL] [Abstract][Full Text] [Related]
15. In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.
Morris ZS; Guy EI; Francis DM; Gressett MM; Werner LR; Carmichael LL; Yang RK; Armstrong EA; Huang S; Navid F; Gillies SD; Korman A; Hank JA; Rakhmilevich AL; Harari PM; Sondel PM
Cancer Res; 2016 Jul; 76(13):3929-41. PubMed ID: 27197149
[TBL] [Abstract][Full Text] [Related]
16. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
[TBL] [Abstract][Full Text] [Related]
17. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
[TBL] [Abstract][Full Text] [Related]
18. ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models.
Jin WJ; Zangl LM; Hyun M; Massoud E; Schroeder K; Alexandridis RA; Morris ZS
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730275
[TBL] [Abstract][Full Text] [Related]
19. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
Rakhmilevich AL; Felder M; Lever L; Slowinski J; Rasmussen K; Hoefges A; Van De Voort TJ; Loibner H; Korman AJ; Gillies SD; Sondel PM
J Immunol; 2017 Feb; 198(4):1575-1584. PubMed ID: 28062694
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of the combination therapy with TNF-alpha gene-modified tumor cells and interleukin 12 in a melanoma model in mice.
Lasek W; Mackiewicz A; Czajka A; Switaj T; Goł b J; Wiznerowicz M; Korczak-Kowalska G; Bakowiec-Iskra EZ; Gryska K; Izycki D; Jakóbisiak M
Cancer Gene Ther; 2000 Dec; 7(12):1581-90. PubMed ID: 11228537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]